Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...
Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...
Background PD-1 blockade has emerged as a promising approach for functional cure of chronic hepatitis B (CHB). Objective This study aimed to evaluate the safety profile of anti-PD-1 antibody (αPD-1), ...
A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic ...
This important study provides a detailed analysis of the transcriptional landscape of the mouse hippocampus in the context of various physiological states. The main conclusions have solid support: ...
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
Secura Bio, Inc. ( an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today provided a corporate update, including an update on the encouraging enrollment ...
Investigators from the laboratory of Derek Walsh, Ph.D., professor of Microbiology-Immunology, have discovered how human ...
The Food and Drug Administration (FDA) has approved updated labeling for Unloxcyt ™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally ...
12d
Mapping pre-myelinating oligodendrocytes: New mouse line links neuronal activity to cell survival
Nerve fibers in the brain and spinal cord are wrapped in an insulating sheath known as myelin. For a long time, this barrier, ...
Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease after a registrational trial showed “highly statistically significant” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results